| 马艳霞,田风胜,崔荣岗,刘 燕,孟莹莹.复荣通脉胶囊联合利拉鲁肽治疗2型糖尿病大血管病变患者的疗效及其作用机制研究[J].,2024,(7):1353-1358 |
| 复荣通脉胶囊联合利拉鲁肽治疗2型糖尿病大血管病变患者的疗效及其作用机制研究 |
| Study on the Efficacy and Mechanism of Furong Tongmai Capsule Combined with Liraglutide in the the Treatment of Type 2 Diabetes Patients with Macroangiopathy |
| 投稿时间：2023-08-24 修订日期：2023-09-21 |
| DOI：10.13241/j.cnki.pmb.2024.07.030 |
| 中文关键词: 复荣通脉胶囊 利拉鲁肽 2型糖尿病 大血管病变 PI3K/AKT信号通路 |
| 英文关键词: Furong Tongmai capsule Lilalutide Type 2 diabetes Macroangiopathy PI3K/AKT signaling pathway |
| 基金项目:河北省中医药管理局2022年度中医药类科研计划课题（2022249） |
|
| 摘要点击次数: 263 |
| 全文下载次数: 212 |
| 中文摘要: |
| 摘要 目的：探讨复荣通脉胶囊联合利拉鲁肽治疗2型糖尿病大血管病变患者的疗效及其作用机制。方法：选择2021年1月-2022年12月河北省沧州中西医结合医院收治的2型糖尿病大血管病变患者160例，按照数字随机法分为A组（n=53，常规治疗）、B组（n=53，常规治疗联合利拉鲁肽）和C组（n=54，在B组的基础上联合复荣通脉胶囊治疗）。观察治疗前后各组颈动脉内膜-中层厚度（IMT）、颈动脉粥样硬化斑块面积、糖代谢指标、血脂指标、血清同型半胱氨酸（Hcy）、超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）水平及磷酸肌醇3激酶（PI3K）/蛋白激酶B（AKT）信号通路关键分子表达量的变化情况。结果：治疗后，C组颈动脉IMT及颈动脉粥样硬化斑块面积显著低于A组和B组，B组颈动脉IMT及颈动脉粥样硬化斑块面积显著低于A组（P<0.05）。治疗后，C组空腹血糖（FPG）、糖化血红蛋白（HbA1c）、餐后2 h血糖（2hPG）、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、血清Hcy、hs-CRP、IL-6、PI3K 信使核糖核酸（mRNA）、AKT mRNA水平显著低于A组和B组，高密度脂蛋白胆固醇（HDL-C）显著高于A组和B组（P<0.05）。结论：复荣通脉胶囊联合利拉鲁肽治疗治疗2型糖尿病大血管病变疗效确切，可有效地降低血糖、调节血脂，发挥抗炎作用，其作用机制可能与调节PI3K/AKT信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy and mechanism of Furong Tongmai Capsules combined with liraglutide in treatment of type 2 diabetes patients with macroangiopathy. Methods: 160 type 2 diabetes patients with macroangiopathy who were admitted toCangzhou Integrated Traditional Chinese and Western Medicine Hospital of Hebei Province from January 2021 to December 2022 were selected, they were divided into group A (n=53, treated with conventional), group B (n=53, treated with conventional combined with liraglutide), and group C (n=54, treated with combined with Furong Tongmai capsule on the basis of group B) according to the random number method.The changes of carotid intima-media thickness (IMT), carotid atherosclerotic plaque area, glucose metabolism indexes, blood lipid indexes, serum homocysteine (Hcy), hypersensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) levels and the expression of key molecules of phosphoinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway were observed before and after treatment in each group. Results: After treatment, the carotid IMT and carotid atherosclerotic plaque area in group C were significantly lower than those in group A and group B, and the carotid IMT and carotid atherosclerotic plaque area in group B were significantly lower than those in group A(P<0.05). After treatment, the fasting plasma glucose (FPG), glycosylated hemoglobin A1c (HbA1c), 2 h postprandial plasma glucose (2hPG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), serum Hcy, hs-CRP, IL-6, PI3K messenger ribonucleic acid (mRNA), AKT mRNA levels in group C were significantly lower than those in group A and group B, and the high-density lipoprotein cholesterol (HDL-C) was significantly higher than that in group A and group B (P<0.05). Conclusion: Furong Tongmai capsule combined with liraglutide is effective in the treatment of type 2 diabetes with macroangiopathy. It can effectively reduce blood glucose, regulate blood lipids, and exert anti-inflammatory effects. Its mechanism may be related to the regulation of PI3K/AKT signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
